$25 Million

Angion

Private Placement

Placement Agent, February 2021

Angion is a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. The Company’s lead product candidate, ANG-3777, is an hepatocyte growth factor (HGF) mimetic and is currently being evaluated in a Phase 3 registration trial to improve graft function and reduce the severity and long-term sequelae of transplant-associated acute kidney injury, also known as delayed graft function (DGF), in patients at risk for kidney dysfunction. The Company is also investigating ANG-3777 in a Phase 2 clinical trial for the treatment of cardiac surgery associated acute kidney injury (CSA-AKI).

More Like This

Jul 2022
$350 Million

Series A Private Placement

Exclusive Placement Agent

View Details >
Jan 2021
$70 Million

Private Placement

Capital Markets Advisor

View Details >
Dec 2020
$336 Million

Initial Public Offering and Concurrent Private Placement

Bookrunner

View Details >